Plural Ring Nitrogens In The Polycyclo Ring System Patents (Class 514/214.02)
-
Publication number: 20090239841Abstract: Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.Type: ApplicationFiled: October 24, 2005Publication date: September 24, 2009Inventors: Alan J. Hutchison, Jun Yuan
-
Publication number: 20090227564Abstract: A drug effective for prevention and therapy of endometriosis is disclosed. The drug for prevention and/or therapy of endometriosis according to the present invention comprises an antiallergic agent as an effective ingredient.Type: ApplicationFiled: May 13, 2009Publication date: September 10, 2009Inventor: Masao SUGAMATA
-
Publication number: 20090203670Abstract: A sheet-like pharmaceutical preparation (dosage form) that quickly disintegrates on contact with moisture, based on hydrophilic polymers for the release of at least one active agent. The dosage form contains an active agent combination for treating depression, and at least one active agent selected from the antidepressant group of drugs. In addition, the use of such a combination of active agents for the production of an orally administrable pharmaceutical product for the treatment of depression, and the therapeutic treatment of depression by oral administration of one of the named pharmaceutical preparations, is provided.Type: ApplicationFiled: June 4, 2007Publication date: August 13, 2009Applicant: LTS Lohmann Therapie-Systeme AGInventors: Hans-Rainer Hoffmann, Reto Brandli, Frank Theobald
-
Publication number: 20090203669Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: November 13, 2006Publication date: August 13, 2009Inventor: Nicholas E. Goeders
-
Publication number: 20090181942Abstract: The present invention relates to tricyclic compounds each represented by the following formula (I): (wherein, R1, R2, R2?, R3, R4, X, Y and Z have the same meanings as defined in the specification); and a drug containing the compound. Since the compounds according to the present invention exhibit an excellent squalene synthetase inhibitory effect and cholesterol synthesis inhibitory effect so that they are useful as a drug such as preventive and/or remedy for diseases in mammals including humans such as hyperlipemia, e.g., hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterolemia and/or arteriosclerosis.Type: ApplicationFiled: October 23, 2006Publication date: July 16, 2009Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kazuyuki Sugita, Masami Otsuka, Hitoshi Oki, Noriyasu Haginoya, Masanori Ichikawa, Masao Itoh
-
Publication number: 20090149446Abstract: The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that include a nicotinic agonist (for example, nicotine) and a nicotinic acetylcholine receptor desensitization inhibitor (for example, opipramol).Type: ApplicationFiled: November 26, 2008Publication date: June 11, 2009Inventor: Eliahu Heldman
-
Publication number: 20090143359Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises epinastine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising epinastine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby causing transfer of a therapeutically effective amount of epinastine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.Type: ApplicationFiled: July 7, 2006Publication date: June 4, 2009Inventors: Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori
-
Patent number: 7538104Abstract: Compounds of the formula I R7?N—R6 RS—C,N—R4 H C, R?/I R, 3 R 2 (I) in which R, is an aromatic or heteroaromatic radical which is capable of absorbing light in the wave-length range from 200 nm to 650 nm and which is unsubstituted or substituted one or more times by C,—C,8alkyl, C2-C,ealkenyl, C2-C,8alkynyl, C,—C,ehaloalkyl, NO2, NR,OR, CN, OR,2, SR,2, C(O)R,3, C(O)OR,4, halogen or a radical of the formula II R˜—N? R6 1 R5-C,N.Type: GrantFiled: October 8, 2002Date of Patent: May 26, 2009Assignee: Ciba Specialty Chemicals CorporationInventors: Gisèle Baudin, Kurt Dietliker, Tunja Jung
-
Publication number: 20090131405Abstract: The invention relates to compounds of formula I: along with pharmaceutical compositions containing the same and methods of use thereof for the treatment of autoimmune disease.Type: ApplicationFiled: May 24, 2007Publication date: May 21, 2009Inventors: Francis Fang, Shawn Schiller, Boris Seletsky, Mark Spyvee
-
Publication number: 20090111794Abstract: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.Type: ApplicationFiled: October 30, 2008Publication date: April 30, 2009Inventors: Genesis M. Bacani, Scott D. Bembenek, Wendy Eccles, James P. Edwards, Matthew T. Epperson, Laurent Gomez, Cheryl A. Grice, Aaron M. Kearney, Adrienne M. Landry-Bayle, Alice Lee-Dutra, Kelly J. McClure, Taraneh Mirzadegan, Alejandro Santillan, JR.
-
Publication number: 20090099153Abstract: This invention relates to novel 8,10-diaza-bicyclo[4.3.1]decane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: May 21, 2007Publication date: April 16, 2009Inventors: Dan Peters, Gunnar M. Olsen, Elsebet Ostergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jeppe Kejser Christensen, Tino Dyhring
-
Publication number: 20090075974Abstract: Disclosed is a pharmaceutical composition for prophylaxis and treatment of pancreatitis comprising a 5-HT2A receptor antagonist as an effective component, wherein the binding activity (pKi) of the 5-HT2A receptor antagonist to a 5-HT2A receptor is higher at least by 1.0 than the binding activities to a 5-HT2B receptor and a 5-HT2C receptor. Preferably the binding activity (pKi) of the 5-HT2A receptor antagonist to the 5-HT2A receptor is at least 7.0, and more preferably at least 8.0. The present invention also provides a method of identifying a candidate substance for prophylactic and therapeutic agent for pancreatitis, comprising determining whether a test substance has a 5-HT2A receptor antagonistic activity.Type: ApplicationFiled: April 27, 2006Publication date: March 19, 2009Applicant: UMN Pharma Inc.Inventors: Isamu Yamaguchi, Kentaro Hamada, Yasunari Kashihara
-
Publication number: 20090069294Abstract: The present disclosure relates to XIAP inhibitor compounds of the formula I.Type: ApplicationFiled: June 6, 2006Publication date: March 12, 2009Inventors: Zhuoliang Chen, Mark G. Palermo, Sushil K. Sharma, Troy Smith, Christopher S. Straub, Run-Ming D. Wang, Yaping Wang, Leigh Zawel
-
Publication number: 20090062253Abstract: The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.Type: ApplicationFiled: August 28, 2008Publication date: March 5, 2009Applicant: KALYPSYS, INC.Inventors: Timothy C. Gahman, Cunxiang Zhao, Hengyuan Lang, Mark Eben Massari
-
Publication number: 20090062257Abstract: The present application describes deuterium-enriched varenicline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 25, 2008Publication date: March 5, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090054403Abstract: Provided are methods of treating a patient diagnosed with post-traumatic stress disorder, by administering to the patient a therapeutically effective amount of Compound A. Also provided are methods of improving resilience in a patient by administering a therapeutically effective amount of Compound A. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of Compound A and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the Compound A reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder.Type: ApplicationFiled: July 23, 2008Publication date: February 26, 2009Applicant: SYNOSIA THERAPEUTICSInventors: Tom Woiwode, Mark Moran
-
Publication number: 20090048232Abstract: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPAR? agonist and one or more other therapeutic agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.Type: ApplicationFiled: April 11, 2008Publication date: February 19, 2009Inventor: Roberto Ciccocioppo
-
Publication number: 20090048233Abstract: Provided are combinations of pharmaceutical agents capable of eliciting a therapeutic effect. A first therapeutic agent in the combination has 5HT2/5HT3 antagonist and alpha-2 antagonist activity. A second therapeutic agent possesses both serotonin reuptake inhibitory activity and norepinephrine reuptake inhibitory activity or is a reversible inhibitor of monoamine oxidase A (RIMA). In some embodiments, a combination of a first therapeutic agent and a second therapeutic agent results in reduction in one or deleterious side effects associated with the first therapeutic agent, the second therapeutic agent or both. Also provided are methods of treatment employing a first therapeutic agent and a second therapeutic agent. Also provided are kits containing a first therapeutic agent, a second therapeutic agent and instructions for administering the first therapeutic agent and the second therapeutic agent.Type: ApplicationFiled: August 15, 2008Publication date: February 19, 2009Applicant: CYPRESS BIOSCIENCES, INC.Inventors: Srinivas RAO, Jay Kranzler, Jeffery J. Anderson
-
Publication number: 20090042861Abstract: The present invention provides a prophylactic or therapeutic agent for depression or anxiety disorders, comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.Type: ApplicationFiled: April 3, 2006Publication date: February 12, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Keisuke Hirai, Masaomi Miyamoto
-
Publication number: 20090036427Abstract: A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: Wherein Y, Z, R1, R2, R3, R4, R5, R6, R7, n, m, and o are as described herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3?, such as Alzheimer disease.Type: ApplicationFiled: May 16, 2008Publication date: February 5, 2009Applicants: SANOFI-AVENTIS, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Nathalie CHEREZE, Alistair LOCHEAD, Mourad SAADY, Franck SLOWINSKI, Philippe YAICHE
-
Publication number: 20090018115Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.Type: ApplicationFiled: September 26, 2008Publication date: January 15, 2009Applicant: Orexigen Therapeutics, Inc.Inventors: Kishore M. Gadde, K. Ranga Krishnan
-
Publication number: 20090017003Abstract: The present invention relates to novel thiosulfonates derivatives. The present invention also provides methods for preventing, treating and/or reducing inflammation-associated diseases in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous or cutaneous systems as well as infective and tumoral diseases employing said compounds.Type: ApplicationFiled: March 1, 2007Publication date: January 15, 2009Applicant: SULFIDRIS S.R.L.Inventors: Piero Del Soldato, Giancarlo Santus, Anna Sparatore
-
Patent number: 7476662Abstract: The invention concerns novel substituted tetracyclic imidazole derivatives useful for the treatment of elevated intracranial pressure (ICP) and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine. The novel compounds comprise compounds according to the general Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-l-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2-?]benzimidazol-4(10H)-one, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof.Type: GrantFiled: June 11, 2002Date of Patent: January 13, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Frans Eduard Janssens, Joseph Elisabeth Leenaerts, Koenraad Arthur Van Rossem, Manuel Jesús Alcázar-Vaca, Pedro Martínez-Jiménez, José Manuel Bartolomé-Nebreda, Antonio Gómez-Sánchez, Francisco Javier Fernández-Gadea, Jos Van Reempts
-
Publication number: 20080317883Abstract: The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more carbamate compounds of Formula 1 and/or Formula 2 as herein defined and shown below for the treatment of depression. The present invention is directed to a method for the treatment of depression, which includes mono-therapy and alternatively, co-therapy with at least one additional antidepressant.Type: ApplicationFiled: October 22, 2007Publication date: December 25, 2008Inventors: Yong Moon Choi, Robert Gordon, Magali Haas, Ewa Malatynska
-
Publication number: 20080305075Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.Type: ApplicationFiled: April 29, 2008Publication date: December 11, 2008Inventors: John G. Curd, John F.W. Keana, Alshad S. Lalani, Paul B. Westberg, Bradford Goodwin, W. David Henner
-
Publication number: 20080267942Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are agonists at the beta-2 adrenoceptor. They are useful as feed additives for livestock animals.Type: ApplicationFiled: April 11, 2008Publication date: October 30, 2008Applicant: Pfizer LimitedInventors: Jessica Boyle, Ashley Edward Fenwick, David Morris Gethin, Catherine Frances McCusker
-
Publication number: 20080254029Abstract: Disclosed are methods of treating allergic conjunctivitis and allergic rhinitis in a subject that involve topically administering to the subject a composition comprising a pharmaceutically effective amount of an H1 antagonist and an anti-TNF? compound.Type: ApplicationFiled: April 10, 2008Publication date: October 16, 2008Applicant: ALCON RESEARCH, LTD.Inventors: John M. Yanni, Daniel A. Gamache, Steven T. Miller, Clay Beauregard
-
Publication number: 20080207593Abstract: A once daily formulation containing the combination of a non-sedating or selective antihistamine (Loratadine) with a sedating or non-selective antihistamine (Chlorpheniramine) administered at bed-time has demonstrated greater efficacy in relieving allergic symptoms than Loratadine alone.Type: ApplicationFiled: August 20, 2007Publication date: August 28, 2008Inventors: Michael Heffernan, Jane C. Hirsh, Roman V. Rariy
-
Publication number: 20080206191Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: February 15, 2008Publication date: August 28, 2008Inventors: Andrew Nickel, John F. Kadow
-
Patent number: 7414045Abstract: Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds of Formula (A): are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16, R30, R32, R34 and R36 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: December 18, 2003Date of Patent: August 19, 2008Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Benedetta Crescenzi, Olaf Kinzel, Ester Muraglia, Federica Orvieto, Giovanna Pescatore, Michael Rowley, Vincenzo Summa
-
Publication number: 20080194544Abstract: There is provided homogeneous pharmaceutical compositions for the treatment of, for example, rhinitis, asthma and/or chronic obstructive pulmonary disease comprising a corticosteroid and an antihistamine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier.Type: ApplicationFiled: June 28, 2007Publication date: August 14, 2008Inventor: RAMESH KRISHNAMOORTHY
-
Publication number: 20080166406Abstract: A rapidly disintegrating dosage form containing magnesium carbonate heavy is described, which disintegrates upon contact with moisture. The dosage forms can be either dispersible or orodispersible tablets and can accommodate widely different active principles. The magnesium carbonate heavy is found to be an excellent dispersant under basic and neutral conditions, and gives the tablets a smooth mouth-feel.Type: ApplicationFiled: March 2, 2006Publication date: July 10, 2008Inventor: Torfi E. Kristjansson
-
Publication number: 20080161288Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are agonists at the beta-2 adrenoceptor. They are useful as feed additives for livestock animals.Type: ApplicationFiled: November 21, 2007Publication date: July 3, 2008Inventors: Jessica Boyle, Ashley Edward Fenwick, David Morris Gethin, Catherine Frances McCusker
-
Publication number: 20080153807Abstract: The use of fused 1,2,4-triazoles for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of fused 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.Type: ApplicationFiled: February 27, 2008Publication date: June 26, 2008Applicant: Novo Nordisk A/SInventors: Henrik Sune Andersen, Gita Camilla Tejlgaard Kampen, Inge Thoger Christensen, John Patrick Mogensen, Annette Rosendal Larsen
-
Publication number: 20080153806Abstract: This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: October 18, 2005Publication date: June 26, 2008Inventors: Dan Peters, Daniel B. Timmermann, Gunnar M. Olsen, Elsebet Ostergaard Nielsen, Tino Dyhring Jorgensen
-
Patent number: 7390798Abstract: The present invention is directed to compounds of Formula I: I (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.Type: GrantFiled: February 9, 2005Date of Patent: June 24, 2008Assignee: Merck & Co., Inc.Inventors: Theresa M. Williams, Christopher S. Burgey, Thomas J. Tucker, Craig A. Stump, Ian M. Bell
-
Publication number: 20080146537Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.Type: ApplicationFiled: November 19, 2007Publication date: June 19, 2008Inventors: John A. Bender, Min Ding, Robert G. Gentles, Piyasena Hewawasam
-
Publication number: 20080139531Abstract: Disclosed are methods of treating a wound in a subject that involve administering to the subject a pharmaceutically effective amount of a composition that includes one or more human connective tissue mast cell stabilizers, wherein administration of the composition results in treatment of the wound. In particular embodiments, the wound is an ophthalmic or dermal wound, such as a corneal epithelial defect, a conjunctival wound, or dermal abrasion. Administration, for example, may be by topical application of the composition to the ocular surface or skin. Exemplary mast cell stabilizers include olopatadine, variants of olopatadine, alcaftidine, derivatives of alcaftidine, dihydropyridines, and spleen tyrosine kinase inhibitors.Type: ApplicationFiled: November 29, 2007Publication date: June 12, 2008Applicant: ALCON MANUFACTURING LTD.Inventors: John M. Yanni, Daniel A. Gamache, Steven T. Miller
-
Publication number: 20080125360Abstract: The present invention relates to PYY or functional equivalents thereof for use in pharmaceutical compositions. The pharmaceutical compositions are in particular useful in the treatment of functional gastrointestinal disorders, such as irritable bowel disease and functional dyspepsia. The invention further relates to methods of treatment using said compositions. Further included is the combination of PYY or functional equivalents thereof with a secondary active ingredient such as an anti-emetic drug.Type: ApplicationFiled: May 18, 2005Publication date: May 29, 2008Inventor: Henrik Nilsson
-
Patent number: 7378082Abstract: The present invention is directed to a method for treating allergic rhinitis without causing an adverse effect of bitter taste. The method comprises administering to a patient an aqueous pharmaceutical formulation comprising 0.1-0.15% (w/v) of epinastine or an acid addition salt thereof, 0.05-0.5% (w/v) of hydroxypropylmethylcellulose to maintain the viscosity between 1.5-10 centipoise, 1-2% (w/v) of propylene glycol, and a buffer to maintain the pH between 5-8, said aqueous epinastine formulation has a tonicity between 200-400 mOsm/kG; the formulation does not contain a sweetening agent. The present invention provides a method for effectively treating allergic rhinitis by delivering a small volume of the epinastine formulation to the nose of a patient using a small volume metered-dose nasal spray pump. The present method does not cause an adverse effect of bitter taste without including sweetening agents in the formulation.Type: GrantFiled: November 5, 2007Date of Patent: May 27, 2008Assignee: Inspire Pharmaceuticals, Inc.Inventor: Ramesh Krishnamoorthy
-
Publication number: 20080103127Abstract: The present invention is a method for the treatment of Disruptive Behavior Disorders including both Conduct Disorder and Oppositional Defiant Disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more carbamate compounds of Formula 1 and/or Formula 2 as herein defined and shown below. The present invention is directed to a method for the treatment of Disruptive Behavior Disorders including both Conduct Disorder and Oppositional Defiant Disorder, which includes mono-therapy and alternatively, co-therapy with at least one additional psychoactive medication.Type: ApplicationFiled: October 11, 2007Publication date: May 1, 2008Inventor: Magali HAAS
-
Publication number: 20080026081Abstract: The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents.Type: ApplicationFiled: November 19, 2004Publication date: January 31, 2008Inventors: Axel Unterbeck, Michael De Vivo, Gregory M. Rose
-
Publication number: 20080003275Abstract: The invention relates to methods and compositions for treating premature ejaculation in a male or prolonging intercourse comprising administering to the male an antidepressant via a route selected from the group consisting of mucosal administration (preferably nasal, buccal or rectal), administration to the lungs (preferably by inhalation), local administration to at least a part of the male genitalia (applied to the penis for example, in the form of a gel) and combinations thereof.Type: ApplicationFiled: July 9, 2004Publication date: January 3, 2008Applicant: Worldwide PE Patent Holdco Pty Ltd.Inventor: Jakov Vaisman
-
Patent number: 7268127Abstract: Described herein are compounds with affinity for the 5-HT6 receptor, which have the general formula I: Wherein A, B, D, E, R1 to R3 and n are described herein. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT6 receptor is implicated, such as schizophrenia.Type: GrantFiled: June 24, 2005Date of Patent: September 11, 2007Assignee: NPS Allelix CorpInventors: Louise Edwards, Abdelmalik Slassi, Ashok Tehim, Tao Xin
-
Publication number: 20070208002Abstract: The invention provides a method to effectively wean a woman from hormonal therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for one or more periods of durations determined by assessment of the effect of a treatment free period, which follows each period of continuous non-hormonal drug treatment.Type: ApplicationFiled: March 6, 2007Publication date: September 6, 2007Applicant: N.V. OrganonInventors: Edward Baker, Simon Johannes van den Berg
-
Patent number: 7262190Abstract: The invention relates to compounds of formula (I): wherein: R1 represents hydrogen, alkyl or cycloalkyl, R2 represents hydrogen, halogen or hydroxy, A represents CR3R4 or NR3 wherein R3 and R4 are as defined in the description, Y represents an alkylene chain as described in the description, X represents NR5R6, S(O)nR7, OR8, C(O)R9, amidino or a heterocycle, their isomers, and addition salts thereof; and medicinal products containing the same which are useful in the prevention or treatment of diseases associated with AMPA flux.Type: GrantFiled: December 8, 2005Date of Patent: August 28, 2007Assignee: Les Laboratoires ServierInventors: Patrice Desos, Alexis Cordi, Pierre Lestage, Laurence Danober
-
Patent number: 7247623Abstract: A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the eyes of the subject a non-drying antihistamine compound, such as epinastine hydrochloride, in an amount effective to reduce dry eye symptoms and stimulate tear fluid secretion. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the compound include topical administration via a liquid, gel, cream, or as part of a contact lens or a continuous or selective release device; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.Type: GrantFiled: August 10, 2006Date of Patent: July 24, 2007Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Jason L. Vittitow, John C. Ice, Jr.
-
Patent number: 7220737Abstract: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.Type: GrantFiled: September 3, 1998Date of Patent: May 22, 2007Assignee: Novoneuron, IncInventor: Deborah C. Mash
-
Patent number: 7202238Abstract: The present invention relates to a group of unique diazabicyclo alkane derivatives having interesting neurokinin-NK1 receptor antagonistic activity represented by the general formula (1) wherein: R1 represents phenyl, 2-indolyl, 3-indolyl, 3-indazolyl or benzo[b]thiophen-3-yl, which groups may be substituted with halogen or alkyl (1–3C), R2 and R3 independently represent halogen, H, OCH3, CH3 and CF3, R4, R5 and R6 independently represent H, OH, O-alkyl(1–4C), CH2OH, NH2, dialkyl(1–3C)N, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or morpholin-4-yl substituted with one or two methyl or methoxymethyl groups, morpholin-4-ylamino, morpholin-4-ylmethyl, imidazol-1-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl or 3-oxa-8-azabicyclo[3.2.Type: GrantFiled: April 2, 2003Date of Patent: April 10, 2007Assignee: Solvay Pharmaceuticals B.V.Inventors: Dirk de Boer, Hein K. A. C. Coolen, Mayke B. Hesselink, Wouter I. Iwema Bakker, Gijsbert D. Kuil, Jan H. van Maarseveen, Andrew C. McCreary, Gustaaf J. M. van Scharrenburg
-
Patent number: 7173022Abstract: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.Type: GrantFiled: May 26, 2005Date of Patent: February 6, 2007Assignee: Bristol-Myers Squibb CompanyInventors: B. Narasimhulu Naidu, Jacques Banville, John D. Matiskella, Serge Plamondon, Yasutsugu Ueda